Otsuka Holdings Co., Ltd.

OS1.F·Frankfurt·Healthcare
Compare
69.00+2.00 (+2.99%)today
As of Nov 5, 10:30 AM CET · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close67.00
Open69.00
Day range—
52-week range45.0071.00
Off day high0.00%
Off 52-week high−2.82%
Volume13.00
Avg. volume (3M)5.00
Market cap36.15B
EPS (TTM)4.01
Forward P/E—
P/E ratio (TTM)17.21
Dividend yield1.74% (1.13)
Beta (5Y)-0.06
Shares outstanding523.91M
Short interest—
Earnings dateOct 30, 2026
Analyst target—
Profit margin14.40%

Against its peers

Compare in full ›
OS1.F ON4.F D4S.F OFK.F CUP.F AZN
Market cap 36.15B 6.28B 31.06B 14.28B 65.86B 293.14B
P/E (TTM) 17.2 15.4 20.3 21.7 24.0 26.7
Forward P/E — — 46.1 — 0.3 16.7
Price/book 2.0 1.3 3.1 10.2 5.6 5.7
Dividend yield 1.74% 3.63% 3.57% 1.82% 1.93% 1.69%
1-year change +40.76% +18.01% −17.43% +71.74% −1.62% +12.81%
Today +2.99% +4.90% +5.64% +2.99% +4.33% +2.79%

The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.

Latest news

All OS1.F news ›
otsuka-us.com·Positive

Otsuka Presents Landmark Final Phase 3 VISIONARY Results at ASN Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilized Kidney Function and Reduced Risk of Disease Progression and Kidney Failure, Redefining Treatment Paradigm in IgA Nephropathy | Otsuka US

You will now be redirected to www.otsuka-us.com in 20 seconds. Top panel from New England Journal of Medicine, Rizk DV, Barratt J, Suzuki Y, et al, Sibeprenlimab in IgA Nephropathy ─ Final Phase 3 Trial Analysis, Volume No. 396; page…

From the 4Search news index, newest first.

In the news

7mentions in 30 days
7with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use. How to use Finance